See more : Foresight Environmental Infra Ord (FGEN.L) Income Statement Analysis – Financial Results
Complete financial analysis of Myovant Sciences Ltd. (MYOV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Myovant Sciences Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Genfit S.A. (GNFT.PA) Income Statement Analysis – Financial Results
- Grenobloise d’Electronique et d’Automatismes Société Anonyme (GEA.PA) Income Statement Analysis – Financial Results
- Tharimmune, Inc. (THAR) Income Statement Analysis – Financial Results
- Metallis Resources Inc. (MTS.V) Income Statement Analysis – Financial Results
- Xanadu Mines Limited (XAM.AX) Income Statement Analysis – Financial Results
Myovant Sciences Ltd. (MYOV)
About Myovant Sciences Ltd.
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 230.97M | 59.32M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 51.55M | 1.97M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 179.42M | 57.35M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 77.68% | 96.69% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 107.40M | 136.71M | 192.56M | 222.61M | 116.83M | 43.50M |
| General & Administrative | 0.00 | 0.00 | 82.33M | 42.22M | 24.23M | 12.36M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 259.36M | 181.42M | 82.33M | 42.22M | 24.23M | 12.36M |
| Other Expenses | 40.04M | 1.66M | 1.62M | -309.00K | 67.00K | -139.00K |
| Operating Expenses | 366.77M | 318.14M | 274.89M | 264.83M | 141.06M | 55.86M |
| Cost & Expenses | 418.32M | 320.10M | 274.89M | 264.83M | 141.06M | 55.86M |
| Interest Income | 384.00K | 211.00K | 2.55M | 881.00K | 0.00 | 0.00 |
| Interest Expense | 13.97M | 10.40M | 12.66M | 8.82M | 2.05M | 0.00 |
| Depreciation & Amortization | 3.46M | 2.69M | 1.77M | 438.00K | 243.00K | 61.00K |
| EBITDA | -183.89M | -258.09M | -273.80M | -255.88M | -140.75M | 0.00 |
| EBITDA Ratio | -79.62% | -435.11% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -187.35M | -260.78M | -270.71M | -264.83M | -141.06M | -55.86M |
| Operating Income Ratio | -81.11% | -439.64% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -13.59M | 5.99M | -17.51M | -8.25M | -1.98M | -27.66M |
| Income Before Tax | -200.93M | -254.80M | -288.23M | -273.08M | -143.04M | -83.51M |
| Income Before Tax Ratio | -86.99% | -429.55% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 5.05M | 336.00K | 761.00K | 476.00K | 213.00K | -74.00K |
| Net Income | -205.98M | -255.13M | -288.99M | -273.55M | -143.26M | -83.44M |
| Net Income Ratio | -89.18% | -430.12% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.22 | -2.83 | -3.37 | -4.09 | -2.41 | -1.70 |
| EPS Diluted | -2.22 | -2.83 | -3.37 | -4.09 | -2.41 | -1.70 |
| Weighted Avg Shares Out | 92.97M | 90.04M | 85.84M | 66.91M | 59.52M | 49.18M |
| Weighted Avg Shares Out (Dil) | 92.97M | 90.04M | 85.84M | 66.91M | 59.52M | 49.18M |
HealthyWomen and Myovant Sciences Launch “Voices of Periods” to Fight Menstrual Stigma
Myovant Sciences Ltd. (MYOV) CEO Dave Marek on Q3 2020 Results - Earnings Call Transcript
Myovant Sciences: Q3 Earnings Insights
Myovant Sciences (MYOV) Reports Q3 Loss, Tops Revenue Estimates
Myovant Sciences Announces Corporate Updates and Financial Results for Third Quarter of Fiscal Year 2020
Myovant Sciences to Host Third Fiscal Quarter 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on February 11, 2021
Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
Citigroup, Goldman Sachs, JPMorgan, Tesla and More Wednesday Afternoon Analyst Calls
CORRECTION -- Myovant Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference
Source: https://incomestatements.info
Category: Stock Reports